An interventional study of Semi-elemental formula and Standard formula in Traumatic Brain Injury, Neurocritical Care and Enteral Feeding Intolerance, sponsored by Tang-Du Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Tang-Du Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Brain Injuries, Traumatic with a site in China — 29 open to participants now, 30 under way, none of them phase 3. Brain Injuries, Traumatic · China.
Among the 60 studies in Brain Injuries, Traumatic with a site in China, this one is the 10th largest by planned enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2025, is one of 18 with no phase, reaches primary completion later than 15 of the 29 other live ones, and was the 52nd registered.
1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →29 of the 60 studies in Brain Injuries, Traumatic with a site in China are open now. Recruiting first, the newest first:
Zhangjiagang First People's Hospital · Sites in China
Ages 18–65
Shanghai 6th People's Hospital · Sites in China
Ages 18–80 · Healthy volunteers
Huaqiu Zhang · Sites in China
Ages 18–60
Shanxi Bethune Hospital · Sites in China
Ages 18–75
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18–90
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 1 · Phase 4 3
First in 2006; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 52 across 1,091 interventional studies indexed under Brain Injuries, Traumatic.
Median enrollment 83 across the 26 interventional studies, 110 across the 34 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 60 has an industry lead sponsor. The 10 most frequent:
Tang-Du Hospital is the lead sponsor of 167 studies on the registry; 78 are open to participants now.
Tang-Du Hospital has 7 studies filed under Brain Injuries, Traumatic — fewer than ten, so there is no comparison to draw.
7 of the studies in Brain Injuries, Traumatic with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07115459Xiangya Hospital of Central South UniversityDevelopment and Validation of a Prognostic Model for Neurocritical Patients Using Multimodal Brain Monitoring | 2026-12-31 |
| NCT06429774Beijing Tiantan HospitalComparative Effectiveness of Intervention in Multi-level Hospitals for Acute Traumatic Brain Injury(Metric-TBI) | 2026-12-31 |
| NCT04900168Tang-Du HospitalIntracranial Pressure Monitoring in Moderate Traumatic Brain Injury | 2026-12-31 |
| NCT06241482Shanghai 6th People's HospitalSafety and Efficacy of Enhanced Recovery After Surgery in Neurocritical Care | 2027-04-30 |
| NCT06909071Shanxi Bethune HospitalHybrid Closed-Loop System in Neurosurgical Perioperative Hyperglycemia: An Open RCT | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 60 studies in Brain Injuries, Traumatic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study Objective This clinical trial primarily aims to investigate whether semi-elemental enteral nutrition (SEN) improves gastrointestinal tolerance in patients with severe traumatic brain injury (TBI) and to evaluate its impact on clinical outcomes. The safety profile of SEN will also be assessed.
Key Research Questions Does SEN reduce the incidence of acute gastrointestinal injury (AGI) in severe TBI patients?
Study Design
Participants will be randomized 1:1 into either:
Intervention group: Receives SEN initiated within 48 hours post-injury and continued for ≥7 days.
Control group: Receives standard enteral nutrition over the same period.
Background:
Patients with traumatic brain injury (TBI) frequently exhibit gastrointestinal dysfunction secondary to central nervous system impairment. This dysregulation impairs nutrient absorption, exacerbates systemic inflammation, and compromises clinical recovery trajectories. Emerging evidence suggests that semi-elemental enteral nutrition (SEN)-featuring hydrolyzed macronutrients with low-osmolality formulations-may mitigate these sequelae by reducing digestive burden and enhancing mucosal healing. However, robust clinical evidence supporting its superiority over standard enteral feeding in severe TBI populations remains limited.
Objectives:
Primary Objective:
To evaluate the efficacy of semi-elemental enteral nutrition (SEN) in improving gastrointestinal tolerance during the acute phase (first 7 days post-injury) in patients with severe traumatic brain injury (TBI).
Secondary Objectives:
To assess gastrointestinal complications within 7 days of enteral nutrition initiation, including:
Incidence of diarrhea and diarrhea-free days Incidence of constipation Incidence of vomiting Incidence of gastroparesis Incidence of abdominal distension Time to first onset of gastrointestinal intolerance symptoms Duration of gastrointestinal intolerance symptoms
To evaluate clinical outcomes:
Hospitalization duration (total and ICU-specific) 6-month mortality and functional recovery
Infection rates Pneumonia incidence Other adverse events
Study Design:
A multicenter, randomized, double-blind, parallel-group exploratery trial will be conducted. 100 severe TBI patients will be allocated 1:1 to intervention (SEN formula) or control (standard formula) arms within 48 hours of injury.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive semi-elemental enteral nutrition.
Dietary Supplement: Semi-elemental formula
Patients will receive standard enteral nutrition.
Dietary Supplement: Standard formula
Treatment: Semi-elemental enteral nutrition Objective: To assess the efficacy of semi-elemental enteral nutrition in enhancing gastrointestinal tolerance in patients with severe traumatic brain injury.
Treatment: Standard enteral nutrition Objective: To serve as the control for evaluating the efficacy and safety of semi-elemental enteral nutrition versus standard nutritional therapy
Incidence of Gastrointestinal Intolerance
Proportion of patients developing gastrointestinal intolerance within 7 days of enteral nutrition initiation. (Composite endpoint including: vomiting, diarrhea, constipation, gastroparesis, gastrointestinal bleeding, and abdominal distension.)
Time frame: Within 7 days.
Hospitalization length of stay (LOS)
Total length of stay in the hospital.
Time frame: Periprocedural.
NICU LOS
Total length of stay in the neurological intensive care unit (NICU)
Time frame: Periprocedural
In-hospital mortality
Mortality rate in hospital.
Time frame: Periprocedural.
ICU mortality
Mortality rate in NICU
Time frame: Periprocedural
Three-month mortality
Mortality rate at 3-month.
Time frame: Within 3 months.
Six-month mortality
Mortality rate at 6-month.
Time frame: Within 6 months.
Functional outcomes (GOSE)
The Glasgow Outcome Scale-Extended (GOSE) scores at 3 and 6 months. The score ranges from 1 to 8, with higher scores indicating a better outcome.
Time frame: Within 6 months.
Functional outcomes (Barthel)
The Barthel Index scores at 3 and 6 months.The score ranges from 1 to 100, with higher scores indicating a better outcome.
Time frame: Within 6 months.
Gastrointestinal intolerance events
Gastrointestinal intolerance events within 7 days of enteral nutrition initiation, including: 1. Incidence of diarrhea. 2. Diarrhea-free days. 3. Incidence of constipation. 4. Incidence of vomiting. 5. Incidence of gastroparesis. 6. Incidence of abdominal distension. 7. Time to first onset of symptoms. 8. Symptom duration.
Time frame: Within 7 days.
Infection
Infection rate during 14-day period (or throughout hospitalization if discharged earlier).
Time frame: Within 14 days
Plan to share: No — Will be determined in accordance with sponsor requirements.
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Nov 2026, 18 months after the start.
Of 445 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 18 months is below that.
Counting every sponsor, half of 467 studies reached it within 41 months; a quarter within 22 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.